# case_19_node_2

## Outcome

- Run status: complete; final source: LLM.
- Target: gamma-knife/SRS for a new pontine metastasis after intracranial progression on osimertinib in EGFR L858R/T790M metastatic lung adenocarcinoma.
- No direct cutoff-valid outcome evidence was retained. The final answer used no citations, declared low confidence and predicted limited benefit/stability from clinical prior.

## Component audit

- Retrieval found one potentially useful treatment-level analog: an EGFR-mutant lung adenocarcinoma case with radiographic CR after robotic SRS 20 Gy. It did not establish the target dose, device, post-osimertinib setting, 8–12-week outcome, symptoms or survival.
- Evidence Review accepted 15 items: 12 analogs, one partial item and two counters. Ten accepted analog items were low relevance and two had different target entities. ROS1/MET cases, systemic-treatment resistance reports and FLAURA survival background do not answer local SRS response.
- The `counter` role again lacked a strict opposite-outcome requirement; unrelated or incomplete evidence can be mislabeled as counter-evidence.
- AnswerMemory atomicity held. Context correctly kept direct findings empty and stated the limits, but still forwarded eight weak findings. Generate cited none, so most retrieval work did not affect the answer.
- Runtime was 855.8 seconds. Eight rerank calls used 435.2 seconds; Safety Reflection required three attempts and 200.0 seconds, ending with one unterminated-JSON failure and rule-result retention.

## Classification

- Repeated general issue: evidence applicability is not gated before admission; topical SRS/NSCLC similarity dominates missing regimen, molecular, treatment-line, endpoint and time-window dimensions.
- Repeated general issue: weak evidence is accurately caveated but still forwarded, increasing downstream tokens without supporting a claim.
- Positive behavior: Context and Generate respected mismatch boundaries and did not cite weak analogs as direct evidence.
- Skill candidate: local-therapy analogs require matching anatomical target, modality/fractionation, systemic-treatment context, assessment window and reported local/symptom outcome; systemic PFS/OS evidence must not be attributed to local therapy.
